2004
Evaluation of myocardial matrix metalloproteinase (MMP) mediated post-MI remodeling with a novel radiolabeled MMP inhibitor
Su H, Spinale F, Dobrucki1 L, Chow C, Sweterlitsch S, Hu X, Bourke B, Cavaliere P, Hua J, Azure M, Edwards D, Sinusas A. Evaluation of myocardial matrix metalloproteinase (MMP) mediated post-MI remodeling with a novel radiolabeled MMP inhibitor. Journal Of Nuclear Cardiology 2004, 11: s20. DOI: 10.1016/j.nuclcard.2004.06.063.Peer-Reviewed Original ResearchMyocardial infarctionPost-MI remodelingPost-myocardial infarctionMMP activationMMP inhibitorsControl groupSitu zymographyMyocardial matrix metalloproteinasesMI regionMin post injectionControl miceMI miceVentricular remodelingPost-MIMI groupMurine modelNew therapiesMatrix metalloproteinaseMMP activityMatrix metalloproteinasesShort-axis slicesMI areaPost injectionMyocardial retentionMice
2001
Technetium-99m-labeled Myocardial Perfusion Agents: Are They Better than Thallium-201?
Kailasnath P, Sinusas A. Technetium-99m-labeled Myocardial Perfusion Agents: Are They Better than Thallium-201? Cardiology In Review 2001, 9: 160-172. PMID: 11304401, DOI: 10.1097/00045415-200105000-00009.Peer-Reviewed Original ResearchConceptsCoronary artery diseasePerfusion tracerPerfusion agentArtery diseaseMyocardial viabilityThallium-201Perfusion imagingMyocardial perfusion imagingRegional flow heterogeneityPharmacologic stressorChest painMyocardial perfusion agentRisk stratificationAcute assessmentNew perfusion agentTechnetium-99mClinical valueMyocardial uptakeIschemic regionAssessment of viabilityCoronary vasculatureMyocardial flowClearance kineticsMyocardial retentionTracer availability